全文获取类型
收费全文 | 200篇 |
免费 | 28篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 13篇 |
临床医学 | 19篇 |
内科学 | 33篇 |
皮肤病学 | 3篇 |
神经病学 | 11篇 |
特种医学 | 3篇 |
外科学 | 22篇 |
综合类 | 45篇 |
预防医学 | 14篇 |
眼科学 | 1篇 |
药学 | 16篇 |
中国医学 | 3篇 |
肿瘤学 | 42篇 |
出版年
2024年 | 3篇 |
2023年 | 14篇 |
2022年 | 41篇 |
2021年 | 16篇 |
2020年 | 14篇 |
2019年 | 5篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 9篇 |
2014年 | 13篇 |
2013年 | 28篇 |
2012年 | 11篇 |
2011年 | 14篇 |
2010年 | 10篇 |
2009年 | 16篇 |
2008年 | 6篇 |
2007年 | 4篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2003年 | 1篇 |
2002年 | 3篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1992年 | 1篇 |
1988年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有232条查询结果,搜索用时 62 毫秒
221.
《Journal of thoracic oncology》2022,17(10):1192-1204
IntroductionBefotertinib (D-0316) is a novel, third-generation EGFR tyrosine kinase inhibitor (TKI). This study evaluated befotertinib in patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy.MethodsThis was a single-arm, open-label, phase 2 study at 49 hospitals across mainland China. Patients with locally advanced or metastatic NSCLC harboring EGFR T790M mutations with disease progression after prior first- or second-generation EGFR TKI therapy received oral befotertinib of 50 mg (cohort A) or 75 to 100 mg (cohort B) once daily. The primary end point was objective response rate (ORR) assessed by an independent review committee in intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT03861156.ResultsA total of 176 patients and 290 patients were included in cohorts A (50 mg) and B (75–100 mg), respectively. At data cutoff (August 15, 2021), independent review committee–assessed ORR was 67.6% (95% confidence interval [CI]: 61.9%–72.9%) in cohort B. The investigator-assessed ORR was 54.0% (95% CI: 46.3%–61.5%) in cohort A and 65.9% (95% CI: 60.1%–71.3%) in cohort B. The median investigator-assessed progression-free survival was 11.0 (95% CI: 9.6–12.5) months in cohort A and 12.5 (95% CI: 11.1–13.8) months in cohort B. The median independent review committee–assessed progression-free survival in cohort B was 16.6 (95% CI: 15.0–not evaluable [NE]) months. The intracranial ORR was 26.7% (95% CI: 7.8%–55.1%) in cohort A by investigator assessment, while 57.1% (95% CI: 34.0%–78.2%) and 55.9% (95% CI: 37.9%–72.8%) in cohort B by investigator and independent review committee assessment, respectively. The median investigator-assessed intracranial progression-free survival was 16.5 (95% CI: 8.6–NE) months in cohort A, while the median intracranial progression-free survival was not evaluable in cohort B due to immature data regardless of investigator or independent review committee assessment. and NE (95% CI: 13.8–NE) in cohort B. The overall survival was immature. Grade 3 or higher treatment-related adverse events and treatment-related serious adverse events occurred in 20.5% and 11.4% of patients in cohort A and in 29.3% and 10.0% of patients in cohort B, respectively.ConclusionsBefotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation with resistance to first- or second-generation EGFR TKIs. A phase 3 randomized trial is underway (NCT04206072). 相似文献
222.
223.
《Clinical breast cancer》2022,22(4):343-358
BackgroundMale breast cancer (MBC) is often diagnosed at a later stage and with a more unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast conservation (BCT). We sought to assess the practice patterns of neoadjuvant therapy (NT) in MBC patients and the impact on BCT.MethodsMen with nonmetastatic, invasive breast cancer were identified from the National Cancer Database. Patients were categorized as having small (cT1/2) or locally advanced (cT3/4) tumors and by whether they received NT (which included endocrine or chemotherapy). Univariate and multivariable analyses were performed to assess patterns of NT use and rates BCT.ResultsOf 15,151 male patients, 4.8% received NT and 21.6% underwent BCT. NT was more common among males with cT3/4 tumors than those with cT1/2 tumors (8.2 vs. 2.1%, P < .001). Overall, unadjusted rates of BCT were higher for patients receiving NT in the cT3/4 subgroup (19.0 vs. 12.5%, P < .001), a difference which persisted on multivariable analysis. For all patients analyzed, overall survival (OS) did not differ between males who underwent NT and those who did not (110 vs. 122 months, P = .67), but NT was associated with poorer OS in both univariate and multivariate analyses for patients with cT3/4 tumors (both P < .01).ConclusionsMen with invasive breast cancer have an expected low rate of BCT, but NT appears to reduce the use of mastectomy in patients with locally advanced cancers. More work is needed to understand the impacts of BCT on locoregional recurrence and disease-free and overall survival for MBC. 相似文献
224.
目的观察临床路径管理在外科手术中的实施效果。方法随机抽取2014-09~2016-09的5个外科病种,其中实施临床路径管理的358例(计划性剖宫产92例、输尿管结石71例、子宫平滑肌瘤64例、腹股沟疝53例、急性阑尾炎78例)为观察组,未实施临床路径管理的217例(计划性剖宫产56例、输尿管结石43例、子宫平滑肌瘤39例、腹股沟疝32例、急性阑尾炎47例)为对照组,对各病种两组病例的次均住院费用、次均药品住院费用、平均住院日、患者满意度进行观察比较。结果两组比较显示,次均住院费用急性阑尾炎差异不大,其余4个病种差异有统计学意义(P0.05);次均药品费用急性阑尾炎差异不大,其余4个病种差异有统计学意义(P0.05);平均住院日5个病种观察组均低于对照组,差异有统计学意义(P0.05);患者满意度腹股沟疝差异不大,其余4个病种差异有统计学意义(P0.05)。结论临床路径管理不仅能降低次均费用和次均药物费用,而且还能缩短平均住院日以及提升患者满意度。 相似文献
225.
《Journal of thoracic oncology》2022,17(11):1244-1246
226.
《European journal of cancer & clinical oncology》1986,22(7):787-791
Seventy-five patients with previously untreated multiple myeloma were randomly treated with the association of Peptichemio, Vincristine and prednisone (PTC-VCR-P) or of melphalan and P (MPH-P) for first induction therapy. After induction, all responsive patients received MPH and P until relapse, while unresponsive patients received it until unequivocal evidence of disease progression was observed. A second induction therapy with PTC-VCR-P was then administered, except to patients resistant to this association at first induction (who received combination chemotherapy which included cyclophosphamide and adriamycin).The response rate was 58% in the PTC-VCR-P and 41% in the MPH-P group (P > 0.05). The PTC-VCR-P responsive patients experienced a median duration of response shorter than MPH-P responsive patients (20.3 vs 39.7, P = 0.041). Median survival from the start of treatment was 26.2 months in the PTC-VCR-P and 54.1 months in the MPH-P group of patients (P = 0.039).Stage I and II myelomas had the same response rate to PTC-VCR-P and to MPH-P, but their survival was shorter on PTC-VCR-P than on MPH-P (P = 0.014). Stage III myelomas responded more frequently to PTC-VCR-P than to MPH-P (P < 0.02) and there was a trend to survive longer on PTC-VCR-P than on MPH-P (22.0 vs 12.5 months, P > 0.05). 相似文献
227.
228.
《Hepatobiliary & pancreatic diseases international : HBPD INT》2022,21(2):106-112
Mammalian target of rapamycin (mTOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant (LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival (RFS) in hepatocellular carcinoma (HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specific for the first 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.Trial register: Trial registered at http://www.chictr.org.cn: ChiCTR2100042869. 相似文献
229.
230.